First Patient Dosed in Phase 3 Trial Testing Tyvyt as First-line Therapy for Esophageal Cancer

First Esophageal Cancer patient is dosed in Phase 3 clinical trial using immune checkpoint inhibitor Tyvyt (sintilimab injection), in combination with the chemotherapies Taxol (paclitaxel) and Platinol (cisplatin).

Tyvyt is intended to boost anti-cancer immune responses by targeting the PD-1 and PD-L1 proteins. When bound, these two proteins prevent the immune system from attacking cancer cells. By targeting the proteins and blocking their interactions, Tyvyt shows promise in fighting the disease.

Read More
ECAN Day is Wednesday, May 29th!